Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aptamer-Targeted Attenuation of IL-2 Signaling in CD8+ T Cells Enhances Antitumor Immunity.

Molecular therapy : the journal of the American Society of Gene Therapy - 4 Jan 2017

Rajagopalan Anugraha, Berezhnoy Alexey, Schrand Brett, Puplampu-Dove Yvonne, Gilboa Eli

Abstract excerpt

Immune responses elicited against cancer using existing therapies such as vaccines or immune stimulatory antibodies are often not curative. One way to potentiate antitumor immunity is to enhance the long-term persistence of anti-tumor CD8+ T cells. Studies have shown that the persistence of activated CD8+ T cells is negatively impacted by the strength of interleukin 2 (IL-2) signaling. Here, we used small...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aptamers, Nucleotide
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8-Positive T-Lymphocytes

Share to Immunologic Memory

Share to Immunotherapy

Share to Interleukin-2

Share to Interleukin-2 Receptor alpha Subunit

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 28129128
DOI: 10.1016/j.ymthe.2016.10.021
PMCID: PMC5363184

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aptamer-Targeted Attenuation of IL-2 Signaling in CD8+ T Cells Enhances Antitumor Immunity.PMID 28129128Read ↗

Targeting MDA5 enhances tumor immunity through immunogenic cell death and augments the efficacy of immune checkpoint blockadeSemantic proximity Read ↗

Tregs constrain CD8 <sup>+</sup> T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapySemantic proximity Read ↗

Context-dependent triggering of STING-interferon signaling by CD11b agonists supports anti-tumor immunity in mouse models and human cancer patientsSemantic proximity Read ↗

Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunitySemantic proximity Read ↗

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.Semantic proximity Read ↗

Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy.Semantic proximity Read ↗

The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8+ T lymphocyte/Treg cell balance.Semantic proximity Read ↗

A novel tumor-targeted interferon-alpha/-beta receptor 1 antagonist increases replication of oncolytic vesicular stomatitis virus in a mouse mesothelioma modelSemantic proximity Read ↗

Regulation of lymphoid homeostasis by IL-2 receptor signals in vivo.Semantic proximity Read ↗

c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8(+) memory T-cell survival.Semantic proximity Read ↗

RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockadeSemantic proximity Read ↗

Agonistic anti-CD40 converts Tregs into Type 1 effectors within the tumor micro-environmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.